Cartesian Therapeutics, Inc.

NASDAQ:RNAC

Biotechnology

Healthcare
$6.30 -4.15%

-$0.41 today

Market cap
$192.17M
Beta
0.78
P/E (TTM)
-1.7
EPS (TTM)
-$5.65
52W Low $5.60High $15.57

Volume 0.17M

Average 0.26M

RNAC Operating Cash Flow

Cash generated by the company's core business operations during the period.

Cartesian Therapeutics, Inc.NASDAQ: RNAC

Operating Cash Flow · Q1 FY2026 · quarter ended Mar 2026

Operating cash flow dips below year-ago levels

Q1 FY2026 operating cash flow of $22.14M (cash outflow) fell 4.2% year over year, behind the +136.4% change in trailing-twelve-month operating cash flow. Sequentially, it rose 25.0% from the prior quarter. Over 3 fiscal years it compounded at +32.7% a year.

Context

  • Operating cash flow amounted to 2643.6% of revenue in FY2025, up 2582.7 pp from a year earlier.
  • Operating cash flow grew in size in 2 of the last 3 fiscal years.
  • FY2025 was the largest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from -4.2% toward the trailing-twelve-month pace of +136.4%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$22.14M+25.0% QoQ
Last fiscal yearDec 2025
-$73.94M+212.3% YoY
LTMMar 2026
-$72.97M+136.4% YoY
Operating Cash Flow past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-4.2%——
1 year+212.3%——
3-year CAGR+32.7%——
5-year CAGR——
10-year CAGR——

Operating Cash Flow history

USD · from the cash flow

Latest · FY2025
(73.94M) USD
Year-over-year change
-212.3%

Operating Cash Flow vs competitors

How RNAC compares with its peers on the latest reported figures

  • Peers report in different currencies, so operating cash flow is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +136.4% is the highest of 9, against a peer median of +15.8%.
  • Operating cash flow amounts to 4110.9% of revenue for RNAC, versus a peer median of 166.6%.
RNAC Competitors
Operating Cash Flow for RNAC and competitors
Company Period LTM YoY 3-year CAGR% of revenue
IVAInventiva S.A.FY2025€100.98M EUR+17.5%+31.0%2252.6%
RNACCartesian Therapeutics, Inc.LTM Mar 2026$72.97M USD+136.4%+32.7%4110.9%
AARDAardvark Therapeutics, Inc. Common StockLTM Mar 2026$61.65M USD+126.0%+72.6%—
AVTXAvalo Therapeutics, Inc.LTM Mar 2026$59.69M USD+14.1%+24.4%101172.9%
OBIOOrchestra BioMed Holdings, Inc.LTM Mar 2026$54.52M USD+0.8%+18.7%166.6%
NAUTNautilus Biotechnology, Inc.LTM Mar 2026$49.86M USD-12.2%+3.4%—
EPRXEupraxia Pharmaceuticals Inc.LTM Mar 2026$31.43M USD+25.2%+26.3%—
NTHINeonc Technologies Holdings, Inc.LTM Mar 2026$21.71M USD———
MDWDMediWound Ltd.LTM Mar 2026$17.86M USD+36.0%+6.9%123.3%
FENCFennec Pharmaceuticals Inc.LTM Mar 2026$5.78M USD-64.7%-11.6%11.3%
Peer median (excluding RNAC) —+15.8%+21.5%166.6%

Competitors are the stored peer set for RNAC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(25.69M)35.38M(219.71M)(77.42M)(130.3M)
Depreciation & Amortization1.25M1.29M843K1.15M2.96M
Deferred Income Tax2.4M(21.4M)(19M)287K(9.19M)
Stock-Based Compensation7.72M11.19M22.52M6.58M10.52M
Change in Working Capital(48.19M)(60.38M)4.97M(5.79M)(8.06M)
Accounts Receivables(2.69M)3.32M907K7.98M(243K)
Inventory211K920K000
Accounts Payables(219K)92K2.83M(2.93M)1.07M
Other Working Capital(45.5M)(64.71M)1.23M(10.84M)(8.89M)
Other Non-Cash Items2.13M2.29M159.21M51.52M60.14M
Operating Cash Flow(60.38M)(31.63M)(51.16M)(23.67M)(73.94M)
Capital Expenditures(1.09M)(1.2M)(206K)(9.09M)(5.45M)
Acquisitions (Net)006.56M351K0
Purchases of Investments(32.46M)(33.5M)000
Sales of Investments16.4M19.7M28.25M00
Other Investing Activities00000
Investing Cash Flow(17.14M)(15M)34.61M(8.74M)(5.45M)
Debt Repayment00(27.46M)00
Common Stock Issued51.96M38.98M0124.44M(301K)
Common Stock Repurchased00(6.17M)00
Dividends Paid00000
Other Financing Activities939K235K231K3.99M(7.75M)
Financing Cash Flow52.9M39.22M(13.15M)168.43M(8.06M)
Effect of Forex Changes(3K)20K(53K)(21K)45K
Net Change in Cash(24.63M)(7.4M)(29.75M)135.99M(87.41M)
Free Cash Flow(61.47M)(32.83M)(51.37M)(32.77M)(79.4M)

Cartesian Therapeutics, Inc.

NASDAQ:RNAC

Intrinsic Alpha fair value

Locked

Current Price

$6.30

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.